Whether it’s a new product enabling ground-breaking research, a strategic partnership with a customer, or a charitable partnership that supports our mission, we’ve always got something going on. Below you’ll find our most recent press releases as well as a filter to further streamline your search.
Jun 09, 2021
MilliporeSigma will hold a collaborative seminar with the Korea Federation of Women’s Science and Technology Associations (KOFWST) about ways to ensure a safe and healthy laboratory environment for pregnant scientists.
May 26, 2021
To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule.
May 20, 2021
MilliporeSigma today introduced a new solution improving productivity in the lab through a more flexible and streamlined nucleic acid purification process — GenElute™-E Single Spin purification kits.
May 18, 2021
MilliporeSigma today announced that VectorY has been selected as the European winner of its 2021 Advance Biotech Grant Program.
May 04, 2021
MilliporeSigma today announced a partnership with Topco Scientific Co. (TSC), a leading semiconductor supplier in Taiwan, to increase the use of more sustainable materials for the electronics industry.
Mar 30, 2021
MilliporeSigma today announced a strategic partnership with the Universitas Indonesia (FMIPA-UI) to establish the first Collaboration Laboratory between the company and the university.
Mar 17, 2021
MilliporeSigma will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Mar 15, 2021
As part of its ongoing commitment to renewable energy, MilliporeSigma has signed a 12-year, off-site, virtual power purchase agreement with Enel Green Power for the construction of a future wind and storage project in Texas.
Feb 15, 2021
MilliporeSigma has launched an enhanced Design for Sustainability (DfS) framework, a unique approach to holistically integrate sustainability into products, systems and services.
Feb 04, 2021
Building on its commitment to accelerate scientific research and science education, MilliporeSigma has announced seven expanded partnerships with leading nonprofit organizations across the world.
Jan 07, 2021
MilliporeSigma today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO).
Dec 07, 2020
MilliporeSigma today announced the broadening of its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.
Nov 10, 2020
MilliporeSigma today announced that its first-to-market Blazar™ platform from the BioReliance® portfolio has won R&D 100 and CPhI Awards for its ability to reduce testing times by up to 80 percent.
Nov 07, 2020
MilliporeSigma and Transcenta, a global biotherapeutics company, have announced a strategic technology collaboration to implement continuous manufacturing for protein therapeutics.
Nov 06, 2020
MilliporeSigma today announced the signing of a Letter of Intent with Donghao Lansheng (Group) Co., Ltd.
Oct 18, 2020
MilliporeSigma today announced that Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of its 2020 Advance Biotech Grant Program.
Oct 12, 2020
MilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform.
Oct 11, 2020
MilliporeSigma today announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada, and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California.
Oct 07, 2020
MilliporeSigma is collaborating with D1Med, a Shanghai-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.
Oct 07, 2020
MilliporeSigma today celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany.
Oct 05, 2020
MilliporeSigma today inaugurated a new $14.4 million industrial water treatment plant at its Jaffrey, New Hampshire, location.
Sep 08, 2020
MilliporeSigma today announced a $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.
Sep 02, 2020
MilliporeSigma today announced the donation of research instruments and materials worth IDR 1.2 billion (€ 74,000) to support the efforts of Eijkman Institute for Molecular Biology, Indonesia
Jul 29, 2020
MilliporeSigma’s DOZN™ Green Chemistry Tool Named Top Project of the Year by Environment + Energy Leader
MilliporeSigma today announced that it won a Top Project of the Year award from Environment + Energy Leader for the company’s DOZN™ system.
Jul 14, 2020
MilliporeSigma has announced plans to build a new, $20 million laboratory facility in Buchs, Switzerland to support its rapidly growing reference materials business.
Jul 09, 2020
MilliporeSigma today opened its M Lab™ Collaboration Center in Shanghai, the company’s largest of nine centers worldwide.
Jul 05, 2020
MilliporeSigma today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program.
Jun 30, 2020
MilliporeSigma today enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring.
Jun 30, 2020
A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.
Jun 09, 2020
MilliporeSigma and 10x Genomics, Inc., a single cell and spatial genomics technologies company, today announced that they have developed a powerful new option for biological experiments.
May 26, 2020
MilliporeSigma and Baylor College of Medicine today announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase 1 clinical trials.
May 11, 2020
MilliporeSigma today announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States.
Apr 30, 2020
MilliporeSigma today unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation.
Apr 21, 2020
MilliporeSigma today announced a second Carlsbad, California-based facility for its BioReliance® viral and gene therapy service offering.
Apr 13, 2020
MilliporeSigma and The Jenner Institute today announced that The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
Apr 06, 2020
MilliporeSigma today announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology.
Mar 02, 2020
MilliporeSigma today launched its LANEXO™ Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Feb 17, 2020
MilliporeSigma today announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits.
Feb 10, 2020
MilliporeSigma today introduced its BrightLab™ cloud-based inventory management and instrument connectivity platform for research scientists.
Jan 09, 2020
MilliporeSigma today announced the opening of new, non-profit center where Indian students and researchers can learn the latest genome-editing and single-molecule biomolecule biomarker detection technologies from MilliporeSigma experts.
Dec 18, 2019
MilliporeSigma today announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, access to MilliporeSigma’s foundational CRISPR intellectual property.
Nov 25, 2019
MilliporeSigma today announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed its patent application for the use of paired CRISPR nickases, bringing MilliporeSigma’s number of patents to 22 worldwide.
Nov 17, 2019
MilliporeSigma today announced the completion of a £9 million expansion to its Gillingham distribution center.
Nov 17, 2019
MilliporeSigma today announced it has received a prestigious R&D 100 Award for its Eshmuno® CP-FT Resin, a first-to-market product used in biopharmaceutical manufacturing.
Nov 11, 2019
MilliporeSigma today announced that it has signed a license agreement providing Evotec SE access to MilliporeSigma’s foundational CRISPR intellectual property.
Oct 18, 2019
MilliporeSigma today announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing.
Sep 18, 2019
MilliporeSigma has launched its official flagship store on Alibaba’s 1688.com.
Sep 18, 2019
MilliporeSigma today announced an expansion of its Singapore biosafety testing laboratory services.
Aug 18, 2019
MilliporeSigma today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma’s patent application claims covering CRISPR gene-editing technology.
Aug 05, 2019
MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and lon
Jul 23, 2019
MilliporeSigma to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics
MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for a collaboration on the development and manufacture of biologics for the treatment of solid tumors.
Jul 17, 2019
MilliporeSigma and the Broad Institute of MIT and Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.
Jun 19, 2019
MilliporeSigma today announced a national campus tour in China for the company’s first mobile protein research laboratory.
Jun 19, 2019
Merck KGaA, Darmstadt, Germany, today announced that its Massachusetts-based business sectors, MilliporeSigma, EMD Serono and EMD Performance Materials, have been named to the Boston Business Journal’s annual “Best Places to Work".
May 29, 2019
MilliporeSigma today announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center.
May 28, 2019
MilliporeSigma today announced that students from St Aloysius’ College in Carrigtwohill have won the company’s 2019 School Science Competition, now in its 15th year.
May 26, 2019
MilliporeSigma today announced the completion of a £2.7 million expansion to its Irvine biopharmaceutical production facility.
May 21, 2019
Merck KGaA, Darmstadt, Germany, today hosted a panel discussion on the occasion of the 72nd World Health Assembly in Geneva, Switzerland.
May 19, 2019
MilliporeSigma today announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative.
May 06, 2019
MilliporeSigma today announced that MDL, a team from Beijing University, has won the company’s first Retrosynthetic Reaction Prediction Contest.
Apr 29, 2019
MilliporeSigma today announced the handover of a fully equipped microbiological testing laboratory to the Food Safety and Standards Authority of India (FSSAI).
Apr 23, 2019
MilliporeSigma today launched Cyrene™ — a sustainable dipolar aprotic solvent, produced in two steps from a renewable cellulose source.
Apr 03, 2019
MilliporeSigma today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next- generation bioprocessing.
Apr 01, 2019
MilliporeSigma today unveiled its BioContinuum™ Buffer Delivery Platform, a new building block in the BioContinuum™ Platform for next-generation bioprocessing, at INTERPHEX in New York City.
Mar 19, 2019
MilliporeSigma today officially opened its new M Lab™ Collaboration Center in Molsheim, France.
Mar 18, 2019
MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
Mar 17, 2019
MilliporeSigma today announced a new cloud-based, remote lab water service and monitoring capability available on all Milli-Q® CLX 7000 clinical water purification systems.
Mar 13, 2019
MilliporeSigma today announced a CRISPR core partnership with Zhejiang University in Hangzhou, China.
Mar 04, 2019
MilliporeSigma today announced that the Canadian Patent Office has allowed MilliporeSigma’s patent application directed to the use of paired CRISPR nickases in eukaryotic cells.
Feb 18, 2019
MilliporeSigma today announced that the U.S. Patent and Trademark Office has issued a formal notice allowing MilliporeSigma’s patent application directed to its proxy-CRISPR technology.
Feb 03, 2019
MilliporeSigma today announced the winners of its Advance Biotech Grant program in Europe. The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market.
Jan 14, 2019
MilliporeSigma today announced that it has been recognized by BioInformatics LLC with a 2018 Life Science Industry Award® for best use of social media.
Dec 18, 2018
MilliporeSigma today announced it has extended and expanded its collaboration with Kuraray Europe to exclusively supply pharmaceutical polyvinyl alcohol (PVA) grades and improvements to benefit the pharmaceutical market.
Dec 09, 2018
MilliporeSigma today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.